RAGE Cytosolic Partner Diaph1 Does Not Play an Essential Role in Diabetic Peripheral Neuropathy Progression

Kamila Zglejc-Waszak1, Bernard Kordas2, Agnieszka Korytko2

  • 1Department of Anatomy and Histology, Faculty of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, 10-085 Olsztyn, Poland.

Cells
|October 28, 2025
PubMed

Insights

Complete loss of Diaphanous-related formin 1 (Diaph1) does not fully prevent diabetic peripheral neuropathy (DPN) in mice. While Diaph1 knockout mice showed some improvements, nerve damage and function deficits persisted, indicating Diaph1 is insufficient alone to halt DPN progression.

Area of Science:

  • Neuroscience
  • Endocrinology
  • Molecular Biology

Background:

  • Diabetic peripheral neuropathy (DPN) is a complication linked to Receptor for Advanced Glycation End-products (RAGE) activation.
  • RAGE signaling involves diaphanous-related formin 1 (Diaph1), a protein crucial for actin organization.
  • Previous studies suggest disrupting RAGE-Diaph1 interactions may alleviate diabetic complications.

Purpose of the Study:

  • To investigate the role of Diaph1 in the progression of diabetic peripheral neuropathy.
  • To determine if complete Diaph1 deficiency can prevent or ameliorate DPN in a mouse model.

Main Methods:

  • Utilized a Diaph1 knockout mouse (DKO) model to study DPN.
  • Assessed systemic effects (weight loss) and sciatic nerve (SCN) changes, including β-actin levels, axonal/fiber diameters, g-ratio, and myelin integrity.
  • Evaluated motor and sensory nerve conduction velocities over six months.

Main Results:

  • CRISPR deletion of Diaph1 did not prevent diabetes-induced weight loss.
  • Diaph1 deficiency failed to prevent hyperglycemia-induced loss of β-actin in sciatic nerve fibers.
  • Partial morphological rescue was observed in DPN, with improved axonal/fiber diameters but incomplete recovery of g-ratio and myelin.
  • Diaph1 knockout did not rescue motor or sensory nerve conduction defects.

Conclusions:

  • Complete loss of Diaph1 is insufficient to halt the progression of diabetic peripheral neuropathy.
  • DKO diabetic mice exhibited some improvements compared to wild-type diabetic mice in parameters like body weight and nerve morphology.
  • Further research is needed to understand the complex mechanisms underlying DPN and identify effective therapeutic targets.